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About BioMed Central
BioMed Central Limited is an independent publishing house committed to
providing immediate free access to peer-reviewed biomedical research. This
is known as Open Access.
All the original research articles in journals published by BioMed Central are
immediately and permanently available online without charge or any other
barriers to access. This commitment is based on the view that open access to
research is central to rapid and efficient progress in science and that
subscription-based access to research is hindering rather than helping
scientific communication.
BioMed Central is committed to ensuring efficient and effective quality
control through full and stringent peer review of the research it publishes.
BioMed Central publishes a wide variety of journals and other services.
BioMed Central's portfolio of over 100 journals ranges from the highly
selective, general interest Journal of Biology, which publishes both online and
in print, to a range of specialist online only journals. BioMed Central also
publishes Faculty of 1000, the leading literature evaluation service.
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Premise
Free and unrestricted availability of biomedical research findings*
(known as Open Access) is technically possible, financially viable, and of
great benefit to the advancement of research.  It should also be the right
of any interested member of the public to have free access to publications
describing the results of publicly funded research.
* For the avoidance of doubt, published research findings are what is also known as primary
research literature, and does not refer to so-called secondary publications such as literature
reviews, news, commentaries, and other information services.

Science Publishing
A.  Present situation
1. Most scientific literature is now available online, but the potential for
universal availability with the associated benefits for science and society at
large are not realised due to the inherently restrictive practices of economic
publishing models based on subscriptions or access licences, which are still
the prevailing norm.
2. The subscription model was well suited to print publications, but does not do
justice to the potential of online publications, which are inappropriately
‘shoehorned’ into this model, severely limiting their potential.
3. As a result, the dissemination and usefulness of scientific research literature is
inadequate for the modern and future needs of scientific discovery.
4. The traditional publishing model is the cause of growing dissatisfaction among
researchers – both in their role of authors and of readers – as well as among
librarians and university administrators, who feel the ever-increasing squeeze
of budget limitations.
5. Free and unrestricted access to research literature increases the visibility of
scientific results, whereas the old, subscription model restricts dissemination.
However, access alone is not sufficient. When results can also be freely used,
freely re-analysed, and freely re-distributed, their usefulness and impact is
increased and scientists in their role as both authors and readers benefit, as
does anyone interested in research results, such as teachers, students, health-
related workers, patients and their families, administrators and policy-makers,
journalists, and any other interested parties.
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6. Whilst very strong economic arguments exist for free access benefiting
scholarly libraries, they are not the most important: the future of science
requires the benefits of full availability of the science literature including the
possibilities of free and unrestricted re-distribution and use. Free availability
and usability of the full-text also ensures proper indexing by search services
such as Google and others, which greatly enhances the ability of the material
to be found.
7. A few science publishers – one of the first and largest of which is our UK-
based company, BioMed Central Limited, and another is the Public Library of
Science in the USA – have pioneered a radically new publishing model that
ensures universal, barrier-free (i.e. gratis and without the requirement to
register) online access, now commonly known as Open Access.

B. Open Access
8. The definition* of Open Access that we use at BioMed Central has three,
equally important, elements:
• The universal and permanent free online availability of research
articles in an easily readable and re-usable format;
• The affirmation from the author (or copyright holder) that the material
can be used, re-used, reproduced, and disseminated freely, on
condition that it is correctly cited;
• Permanent secure archiving and perpetual barrier-free access to and
usability of research articles. (This is ensured by requiring that Open
Access research articles be archived in at least one, and preferably
more, widely and internationally recognised archive committed to
providing Open Access to the medical and life science research
literature, such as PubMed Central.)
*For the avoidance of misunderstanding: Open Access is a property of individual articles, not
necessarily of journals or publishers.
9. This definition has, in essence, been accepted and adopted by funding bodies
as diverse as the Howard Hughes Medical Institute (USA), the Wellcome
Trust (UK), the Max Planck Society (Germany), the German Research
Council (DFG), the French Scientific Research Council (CNRS) and the
French National Medical Research Institute (INSERM). It is also used by the
recently started publishing venture Public Library of Science (USA).
10. The Open Access publishing model recognises that publishing carries a cost,
but instead of paying the cost out of subscription income, with its associated
restrictive consequences, it derives its income from ‘article processing
charges’ at the input-side of the publishing process. This ensures that there are
no restrictions to universal dissemination, access, or usage of the published
research.
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C. Open Access is beneficial for all biomedical science, but urgently needed
for medical research
11. A substantial amount of biomedical research in the UK is publicly funded.
Currently, about 30% of SET (Science Engineering Technology) R&D is
public money (£5 billion out of a total of £17 billion), according to DTI
figures.
12. Results from this research are likely to have a substantial impact on the
quality, ease and efficiency of providing medical care, and on facilitating
further biomedical research.
13. Results of a significant proportion of this research are currently never
published, because journals (or researchers themselves) are unwilling or not
interested in publishing them.
14. There are strong arguments that all citizens should have unrestricted access to
the published results of publicly funded biomedical research:
 i. Clinicians will be able to provide better care;
 ii. Researchers will be able to speed up research and minimize
duplication;
 iii. Patients will be better and more fully informed about the medical
options available to them.
15. Currently, most of the results that are published appear in journals that
severely restrict access to this information to those who have paid a
subscription or access licence. Significant segments of the interested
community and of the intended audience do not have easy access to this
information, including teachers, students, patients and their families, health-
related workers, administrators and policy-makers, journalists, and frequently
also researchers in institutions without subscriptions to all the relevant
literature.
16. Scientists, science administrators and funding bodies have been aware for
some time of the flaws in the current system and are beginning to act to
change the situation. Many would support the introduction of a requirement
that a) all sound publicly funded (biomedical) research must be published; and
b) all this research must be published under the Open Access rules which
guarantee free and unrestricted access, the right to redistribute and to use the
information contained in the published results for any other legitimate
purpose.
17. All Open Access proponents agree that research findings should not be
published without having undergone proper peer-review in order to ensure that
the information is presented correctly, fully and without exaggeration.

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D. Government intervention
18. Government intervention is needed because of the benefits of Open Access to
science and society at large. The tools and infrastructure exist (internet) and
the cost is likely to be considerably lower than with the traditional publishing
model. Yet the widespread adoption of Open Access is hampered by the usual
objections to change and the deeply ingrained system of judging publications,
for the purpose of grants or careers, by the Impact Factor of the journals they
appear in. Whilst we believe that, given time, the benefits of Open Access are
strong enough that they would on their own win over the academic
community, obtaining the benefits for science and society in the short term
requires additional stimuli for the development and growth of Open Access.
19. Because we believe that unrestricted access to findings of publicly funded
medical research is a right of all citizens, we urge the UK Government to
mandate that research results obtained from publicly funded medical
research (most urgently those from clinical trials) are published under
Open Access rules. Note that this requirement does not restrict publication to
Open Access journals, but would require any journal publishing such research
findings to accept the Open Access rules for the article in question. Many
subscription journals are in fact already operating or considering operating a
mixed publishing model, allowing some papers to be published under Open
Access rules.

E. The specific points on which the Committee is inviting written evidence
Q1. What impact do publishers' current policies on pricing and provision
of scientific journals, particularly "big deal schemes", have on libraries
and the teaching and research communities they serve?
20. The current policies, based around a subscription or access-fee publishing
model for research literature, have a severely limiting effect on the
dissemination and efficient use and re-use of the scientific literature and as a
result also on the spread and usefulness of knowledge. They harm the teaching
and research communities they are meant to serve.
21. The economics of the current scholarly subscription-based journal-publishing
model are unsustainable. It already harms the ability of libraries to provide
substantial and balanced information services to their constituencies. BigDeal
bundling schemes and the prevalence of very high prices for science journals
have led to a budget crisis in libraries in both the sciences and the humanities.
Taming price inflation is not enough. Unless the current model is changed,
academic libraries and universities will be unable to continue providing
researchers, students, and teaching staff with the access they require to the
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world's scholarship and knowledge. Scholars will be unable to make the
results of their research widely available.
22. There are four separate (but related) policies that, particularly when operated
jointly, exacerbate the impediments to teaching and research communities’
access to science literature to such an extent that the academic community
should no longer support them.
23. The first problematic publishing policy is charging for access (be it via
subscriptions, licences, document-delivery, or pay-per-view). For academic
scientists, publishing their actual research results is a necessity, unlike
publishing many other kinds of information, which is optional. A research
publication is unique, only published once, and not interchangeable. A system
in which there are barriers to access compromises the very basic need of
optimal dissemination of scientific knowledge.
24. The second problematic policy is a necessity for the payment-for-access
model, but throws up a barrier in its own right as well. This is the policy of
requiring the author to transfer either all copyrights, or, sometimes, the
exclusive dissemination rights to the publisher. Whilst this may be necessary
for the subscription model to operate properly, it makes subsequent re-use of
research material very cumbersome and sub-optimal, due to the need to obtain
prior permission for many forms of re-use, such as inclusion in course-packs,
textbooks (even if written by the same author as the articles to be included),
databases, et cetera, especially as permission often necessitates a fee. This,
obviously, also hampers dissemination and is, in the case of textbooks and
course-packs, particularly damaging to scientific education.
25. The third is the practice of ‘bundling’ (BigDeal schemes) in which libraries
are deprived of the option to subscribe to only the journals that are relevant to
their institution, or punished for being selective by facing subscription prices
that effectively put the cost of the selection at or near the cost of the entire
bundle. The effect of this is that libraries spend a growing proportion of their
budgets on a decreasing number of bundles and increasingly lack the means to
subscribe to relevant journals from smaller publishing houses (such as
specialised scholarly societies) that publish only one or a few unbundled titles.
This is an impediment to the ability of libraries to tailor their collections
optimally to the research and teaching needs of their institution.
26. The fourth is a practice by some publishers of giving access to’ legacy’
publications and journal archives only to those with a current subscription
rather than making the archives available separately. This locks subscribers
in. This practice needs to be abolished where it is current and made
impossible to implement by those who do not currently do it but might wish to
in the future.
27. The Open Access publishing model suffers from none of the disadvantages
above and offers genuine relief for libraries and the researchers, teachers and
students they serve.

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Q2. What action should Government, academic institutions and
publishers be taking to promote a competitive market in scientific
publications?
28. Research articles are, by necessity, unique, published only once, and not
interchangeable. The same article cannot be published in more than one
journal without causing grave difficulties for the system of citations that gives
science literature its coherence. This makes any given journal a monopoly
preventing a properly functioning competitive market in scientific publications
as long as the reader (or someone on behalf of the reader) has to pay
subscription fees.
29. Because of these inherent monopolies, the current market in scientific
publications is not competitive in the usual economic sense. The problem is
not that any one publisher has control over the market, but rather that any
traditional science publisher has a monopoly on the distribution of every
article it publishes. Readers and libraries are not in a position to make an
economic choice. If they need to read – or provide – a particular research
article, they have to pay the price set by the publisher of the journal in which
it appears. When neither readers nor libraries have an effective economic
choice, prices are not subject to the corrective pressures of a functioning
competitive market.
30. There is no such lack of choice for authors. They can exercise their choice
when deciding to which journal to submit an article for publication (in most
disciplines and on most levels there is more than one option). Open Access
publishing, whereby access to the research literature by the reader is free and
unrestricted, provides a mechanism for payment by the author (or on behalf of
the author) which pays for the cost of providing maximum dissemination
rather than for access.  This mechanism allows economic factors (price) to
play a role in the author’s choice and thus ensures a functioning competitive
market with its natural effect of price moderation.
What Government should do:
31. Given that:
a. the scientific community as well as society at large benefit from
maximal dissemination and optimal re-use of scientific knowledge;
b. the technology to achieve maximal dissemination exists;
c. the cost of the scientific literature is largely borne by the research
establishment in either the Open Access or the traditional publishing
model;
the Government is urged to seek to reverse the traditional publishing models
and encourage a competitive Open Access model, which avoids the limitations
of the traditional model and delivers the benefits of maximal dissemination
and unrestricted use of scientific research literature.
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32. Specifically, Government is urged to:
a. Require that Government-funded research results are freely
available with full Open Access;
b. Mandate that included in any Government grant is an amount
sufficient for the author to pay any reasonable article processing
charges necessary for publishing in Open Access journals.
What academic institutions should do:
33. To accelerate the establishment of the input-paid Open Access model as the
norm for the publication of biomedical research, academic institutions should:
 i. De-couple their tenure, promotion, and funding procedures and
decisions from the metrics that are currently provided for traditional
subscription-based journals, such as citation Impact Factors;
 ii. Judge scientific articles on their intrinsic merits instead. (While new
Open Access journals are not in principle excluded from obtaining
Impact Factors, it is a process that takes at least three years and often
longer, losing valuable time for the benefits that Open Access confers
to science and society, because authors – rightly, in the current
assessment climate – perceive publishing in a new journal without an
Impact Factor as potentially jeopardizing their career prospects.);
 iii. Support the payment for publication at input.
What publishers should do:
34. It is understood that publishing costs money. Open Access is a commercially
viable model to defray those costs. Publishers, including scholarly societies
with a journal-publishing programme, have the expertise and experience to
organise and manage the publishing process and are in a position to expedite
a transition to Open Access. We recommend that publishers review their
current practices in the light of the changed scientific and technological
environment, and make the transition to a viable Open Access publishing
model.
35. We recommend that journal-publishing scholarly societies with a charitable
status stay true to their charitable mission and advance the interests of their
chosen scholarly discipline by providing Open Access to their journals. We
recommend that they do not use their charitable and tax-exempt status to
engage in profitable commercial journal publishing along the traditional
subscription model to raise funds for their other, non-publishing, activities, as
this is, in our view, contrary to their mission.

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Q3. What are the consequences of increasing numbers of open-access
journals, for example for the operation of the Research Assessment
Exercise and other selection processes? Should the Government support
such a trend and, if so, how?
36. Open Access is only relevant to the RAE in the sense that all Open Access
journals are new and therefore do not yet have the reputation that is
universally perceived as being the crucial factor in impressing the RAE
assessors.
37. This perception drives researchers to attempt to publish in a very select
number of journals - a fact much lamented by the researchers but seen as a
necessity.
38. The journals are those with high Impact Factors - an average measure of the
number of citations to papers published in the journal, not a measure of an
individual paper in the journal, and widely recognized as a crude and flawed
measure.
39. The RAE should strongly encourage the development of far more sophisticated
metrics, including the number of downloads of articles online, and should
consider operating some form of positive discrimination in favour of those
who choose to publish in Open Access journals and thereby help to advance
research.

Q4. How effectively are the Legal Deposit Libraries making available
non-print scientific publications to the research community, and what
steps should they be taking in this respect?
40. If and when Legal Deposit Libraries make deposited online scientific research
publications available to the scientific community, they can only do so at a
price arranged with and determined by the publisher or copyright holder.
They are prevented from doing anything else until the publisher or copyright
holder does not, or cannot, make the material available himself any longer.
However, Legal Deposit Libraries are in an excellent position to provide and
preserve an Open Access Archive for all Open Access material that is
available, and in doing so give assurance to the scientific community that
research articles will not be lost or become inaccessible if journals or
publishers disappear.
41. The Government is urged to require that the Legal Deposit Libraries in the
UK provide and preserve Open Access Archives for medical and scientific
Open Access articles published in the UK.

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Q5. What impact will trends in academic journal publishing have on the
risks of scientific fraud and malpractice?
42. Open Access is not expected to have much impact on most scientific fraud and
malpractice per se, but will materially increase the chances that fraud will be
detected because of the ready availability, in full, of Open Access articles. One
specific type of fraud, plagiarism, is especially more likely to be found out if
the full text of articles is available for comparison by readers or by software
designed to detect textual identities.

